AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 19 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., (CLGY) announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 6,423,683 entitled "Microdose Therapy."
This patent delineates methods of treating several peripheral vascular disease states, including female sexual dysfunction and Raynaud disease, using a nitric oxide donor (such as nitroglycerin) or a phosphodiesterase inhibitor, such as sildenafil citrate (Viagra, Pfizer). Diminished levels of endogenous nitric oxide have been associated, at least in part, with these diseases.
It is estimated that the incidence of female sexual dysfunction could be almost double the incidence of male erectile dysfunction. Raynaud disease, a vasoconstrictive condition causing pain and discomfort to the fingers and toes of an estimated 28 million people in the United States, can occur in both men and women.
Recent data indicates that up to 75% of the patients diagnosed with this disease are female. With no currently FDA-approved products on the market, these disease states represent significant unmet medical needs in the field of women's health.
"The issuance of this important patent continues to demonstrate ...